PBT434, Prana’s lead drug in preclinical development for movement disorders, to be profiled in collaborative venture
Scientific Journal Acta Neuropathologica publishes pre-clinical data
David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco.
Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.
Prana today provided a business update on its development portfolio of potential neurodegenerative treatments.
Prana Biotechnology will host a webcast at its Annual General Meeting on Thursday 17th November 2016 at 9.30am AEDT.
Prana today announced that is has received further advice from the US Food and Drug Administration (FDA) on the steps necessary to remove the Partial Clinical Hold (PCH) on PBT2, including the requirement to undertake further non-clinical studies.
Prana has today announced that it has received a A$4.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
Further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster at the American Neurological Association (ANA) Annual Meeting in Baltimore, United States.